{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:45:31Z","timestamp":1782992731747,"version":"3.54.5"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">The ONCO PE (Optimal Duration of Anticoagulation Therapy for Low\u2010Risk Pulmonary Embolism Patients With Cancer) trial demonstrated the superiority of 18\u2010month compared with 6\u2010month rivaroxaban treatment for cancer\u2010associated low\u2010risk pulmonary embolism in reducing recurrent venous thromboembolism. However, it was uncertain whether the results could be applicable to patients with different performance status (PS) scores, which evaluate the physical condition of patients with cancer undergoing anticancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">In this post hoc subgroup analysis of the ONCO PE trial, we compared the 18\u2010month and 6\u2010month rivaroxaban treatment groups in 2 subgroups: the low PS score (no restricted physical activity: PS=0; n=79) and high PS score (restricted physical activity: PS \u22651; n=99) subgroups. The primary end point was recurrent venous thromboembolism, and the major secondary end point was major bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      The rate of recurrent venous thromboembolism was lower in the 18\u2010month rivaroxaban group than in the 6\u2010month rivaroxaban group, significantly among the low PS score subgroup (2.7% versus 19.0%,\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      =0.049) and numerically among the high PS score subgroup without statistical significance (7.7% versus 19.1%,\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      =0.10). The rate of major bleeding was not different between the 2 groups among the low PS score subgroup (2.7% versus 7.1%,\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      =0.39), while it was numerically higher in the 18\u2010month rivaroxaban group than in the 6\u2010month rivaroxaban group among the high PS score subgroup, without statistical significance (11.5% versus 4.3%,\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      =0.20).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Extended anticoagulation therapy for patients with cancer\u2010associated low\u2010risk pulmonary embolism might have a potential benefit in reducing thrombotic risk irrespective of PS score, whereas there might be some concerns on an increased risk of major bleeding in patients with a high PS score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique Identifier: NCT04724460.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.125.045541","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:22:51Z","timestamp":1772187771000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Extended Anticoagulation Therapy With Rivaroxaban for Cancer\u2010Associated Low\u2010Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial"],"prefix":"10.1161","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-8535","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"first","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]},{"name":"Graduate School of Medicine, Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-1321","authenticated-orcid":false,"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-739X","authenticated-orcid":false,"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Hyogo Medical University","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3564-039X","authenticated-orcid":false,"given":"Nao","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center","place":["Shizuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-749X","authenticated-orcid":false,"given":"Wataru","family":"Shioyama","sequence":"additional","affiliation":[{"name":"Shiga University of Medical Science","place":["Otsu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-9314","authenticated-orcid":false,"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Shiga University of Medical Science","place":["Otsu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7622-8494","authenticated-orcid":false,"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[{"name":"Kurashiki Central Hospital","place":["Kurashiki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Kurashiki Central Hospital","place":["Kurashiki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-7604","authenticated-orcid":false,"given":"Tatsuhiro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Kurume University School of Medicine","place":["Kurume, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-3993","authenticated-orcid":false,"given":"Nagisa","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Kurume University School of Medicine","place":["Kurume, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-109X","authenticated-orcid":false,"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Kurume University School of Medicine","place":["Kurume, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-8540","authenticated-orcid":false,"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Osaka General Medical Center","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-980X","authenticated-orcid":false,"given":"Koh","family":"Ono","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Hirakata Kohsai Hospital","place":["Hirakata, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ONCO PE Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32658-1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072715"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz405"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0046"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00294"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-025-03103-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.072758"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2923-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1194-4"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7111"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2024.102527"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06139-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.07.008"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0445"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.02.003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4347"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.09.003"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.125.045541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:12:18Z","timestamp":1782990738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.125.045541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,17]]}},"alternative-id":["10.1161\/JAHA.125.045541"],"URL":"https:\/\/doi.org\/10.1161\/jaha.125.045541","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"2025-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e045541"}}